芦可替尼用于治疗对类固醇耐药的急性移植物抗宿主病。 - Suppr

Suppr

超能文献

Ruxolitinib for steroid-resistant acute GVHD.

作者信息

Risitano Antonio Maria, Peffault de Latour Regis

机构信息

Federico II University of Naples.

Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris.

出版信息

Blood. 2020 May 14;135(20):1721-1722. doi: 10.1182/blood.2020005364.

DOI:10.1182/blood.2020005364

PMID:32407526

Abstract

摘要

相似文献

Ruxolitinib for steroid-resistant acute GVHD.芦可替尼用于治疗对类固醇耐药的急性移植物抗宿主病。

Blood. 2020 May 14;135(20):1721-1722. doi: 10.1182/blood.2020005364.

Ruxolitinib treatment for steroid refractory acute and chronic graft vs host disease in children: Clinical and immunological results.芦可替尼治疗儿童激素耐药性急性和慢性移植物抗宿主病：临床和免疫学结果。

Am J Hematol. 2019 Mar;94(3):319-326. doi: 10.1002/ajh.25376. Epub 2018 Dec 21.

Ruxolitinib salvage therapy is effective for steroid-refractory graft-versus-host disease in children: A single-center experience.芦可替尼挽救治疗儿童激素耐药性移植物抗宿主病：单中心经验。

Pediatr Blood Cancer. 2020 Apr;67(4):e28190. doi: 10.1002/pbc.28190. Epub 2020 Jan 25.

Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628).Ruxolitinib 在移植物抗宿主病（GvHD）中的研究（RIG）：一项多中心、随机的 2 期临床试验，旨在确定 Ruxolitinib 和最佳可用治疗（BAT）在激素难治性急性移植物抗宿主病（aGvHD）中的反应率，与 BAT 相比（NCT02396628）。

BMC Cancer. 2018 Nov 19;18(1):1132. doi: 10.1186/s12885-018-5045-7.

Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation.造血细胞移植后糖皮质激素难治性移植物抗宿主病患者接受芦可替尼治疗的疗效、毒性和感染并发症。

Biol Blood Marrow Transplant. 2019 Aug;25(8):1689-1694. doi: 10.1016/j.bbmt.2019.04.003. Epub 2019 Apr 6.

Beyond ruxolitinib in steroid-refractory acute graft-versus-host disease.除鲁索替尼外治疗类固醇难治性急性移植物抗宿主病的方法

Br J Haematol. 2021 Nov;195(3):306-307. doi: 10.1111/bjh.17735. Epub 2021 Aug 16.

Ruxolitinib for steroid-refractory acute graft-versus-host disease.芦可替尼用于治疗类固醇难治性急性移植物抗宿主病。

Transpl Int. 2020 Feb;33(2):244-246. doi: 10.1111/tri.13560. Epub 2019 Dec 13.

ANZTCT consensus position statement on ruxolitinib in steroid-refractory acute and chronic graft-versus-host disease.ANZTCT 共识立场声明：芦可替尼治疗激素难治性急性和慢性移植物抗宿主病。

Intern Med J. 2023 Dec;53(12):2319-2329. doi: 10.1111/imj.16255. Epub 2023 Nov 28.

Ruxolitinib is an effective salvage treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation without posttransplant cyclophosphamide.芦可替尼是在异基因造血干细胞移植后未使用环磷酰胺的情况下，治疗多药耐药移植物抗宿主病的有效挽救治疗方法。

Ann Hematol. 2021 Jan;100(1):169-180. doi: 10.1007/s00277-020-04273-2. Epub 2020 Nov 7.

Ruxolitinib in steroid refractory graft-vs.-host disease: a case report.鲁索替尼治疗类固醇难治性移植物抗宿主病：一例报告

J Hematol Oncol. 2016 Aug 8;9(1):67. doi: 10.1186/s13045-016-0298-6.

引用本文的文献

Salvage treatment of ruxolitinib for refractory adenovirus-associated hemophagocytic syndrome post-haploidentical allogeneic stem cell transplantation: a case report.芦可替尼挽救治疗单倍体相合异基因造血干细胞移植后难治性腺病毒相关噬血细胞综合征：一例报告

Transl Pediatr. 2024 Jun 30;13(6):994-1000. doi: 10.21037/tp-24-27. Epub 2024 Jun 27.

[Clinical study of the efficacies of ruxolitinib plus low-dose PTCY for acute GVHD prevention after haploidentical transplantation in malignant hematological diseases].鲁索替尼联合小剂量PTCY预防恶性血液病单倍体移植后急性移植物抗宿主病的疗效临床研究

Zhonghua Xue Ye Xue Za Zhi. 2024 Feb 14;45(2):128-133. doi: 10.3760/cma.j.cn121090-20230929-00153.

Typical hemophagocytic syndrome associated with cytomegalovirus infection in an immunocompetent patient: a case report and literature review.免疫功能正常患者伴巨细胞病毒感染的典型噬血细胞综合征：病例报告及文献复习。

J Zhejiang Univ Sci B. 2023 Dec 15;24(12):1159-1164. doi: 10.1631/jzus.B2300232.

Efficacy of Baricitinib in Patients with Refractory Adult-Onset Still's Disease.巴瑞替尼治疗难治性成人Still 病患者的疗效。

Drugs R D. 2023 Jun;23(2):109-120. doi: 10.1007/s40268-023-00417-7. Epub 2023 Apr 3.

Case report: Ruxolitinib as first-line therapy for secondary hemophagocytic lymphohistiocytosis in patients with AIDS.病例报告：鲁索利替尼作为 AIDS 患者继发噬血细胞性淋巴组织细胞增生症一线治疗药物。

Front Immunol. 2022 Oct 3;13:1012643. doi: 10.3389/fimmu.2022.1012643. eCollection 2022.

Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: A meta-analysis.芦可替尼治疗类固醇难治性移植物抗宿主病的疗效和安全性：一项荟萃分析。

Front Immunol. 2022 Aug 4;13:954268. doi: 10.3389/fimmu.2022.954268. eCollection 2022.

JAK inhibitors and COVID-19.JAK 抑制剂与 COVID-19。

J Immunother Cancer. 2022 Apr;10(4). doi: 10.1136/jitc-2021-002838.

Immune Dysregulation and Infectious Complications in MPN Patients Treated With JAK Inhibitors.接受 JAK 抑制剂治疗的 MPN 患者的免疫失调和感染并发症。

Front Immunol. 2021 Nov 19;12:750346. doi: 10.3389/fimmu.2021.750346. eCollection 2021.

Diagnosis and treatment of acute graft-versus-host disease after liver transplantation: Report of six cases.肝移植术后急性移植物抗宿主病的诊断与治疗：6例报告

World J Clin Cases. 2021 Oct 26;9(30):9255-9268. doi: 10.12998/wjcc.v9.i30.9255.

Ruxolitinib Inhibits IFNγ Licensing of Human Bone Marrow Derived Mesenchymal Stromal Cells.芦可替尼抑制人骨髓间充质基质细胞的IFNγ许可作用。

Transplant Cell Ther. 2021 May;27(5):389.e1-389.e10. doi: 10.1016/j.jtct.2021.02.002. Epub 2021 Feb 4.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验